BLLN
Billiontoone Inc. - Ordinary Shares - Class A

133
Mkt Cap
$4.15B
Volume
100,920.00
52W High
$138.70
52W Low
$60.00
PE Ratio
-284.58
BLLN Fundamentals
Price
$90.61
Prev Close
$85.15
Open
$85.50
50D MA
$95.05
Beta
0.00
Avg. Volume
243,393.10
EPS (Annual)
-$0.9296
P/B
-17.31
Loading...
Loading...
News
all
press releases
Billiontoone (NASDAQ:BLLN) Trading 6.3% Higher - Still a Buy?
Billiontoone (NASDAQ:BLLN) Trading 6.3% Higher - Here's What Happened...
MarketBeat·13d ago
News Placeholder
More News
News Placeholder
Billiontoone (NASDAQ:BLLN) Sets New 1-Year Low - What's Next?
Billiontoone (NASDAQ:BLLN) Hits New 12-Month Low - What's Next...
MarketBeat·18d ago
News Placeholder
Billiontoone, Inc. (NASDAQ:BLLN) Receives Consensus Rating of "Moderate Buy" from Brokerages
Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three...
MarketBeat·19d ago
News Placeholder
BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare
BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across...
PR Newswire·24d ago
News Placeholder
Billiontoone (NASDAQ:BLLN) Stock Price Down 6% - Here's What Happened
Billiontoone (NASDAQ:BLLN) Stock Price Down 6% - Should You Sell...
MarketBeat·25d ago
News Placeholder
BillionToOne Showcases Single-Molecule NGS at JPMorgan, Lifts 2025 26 Revenue Outlook
Billiontoone (NASDAQ:BLLN) used its presentation at the JPMorgan Healthcare Conference to highlight what management described as a single molecule next-generation sequencing platform that it believes...
MarketBeat·26d ago
News Placeholder
Billiontoone (NASDAQ:BLLN) Trading Up 9.4% - Should You Buy?
Billiontoone (NASDAQ:BLLN) Trading 9.4% Higher - Here's What Happened...
MarketBeat·27d ago
News Placeholder
BillionToOne Backs Annual Outlook; Initiates 2026 Revenue Guidance Above View
(RTTNews) - BillionToOne, Inc.(BLLN), a molecular diagnostics company, on Monday reaffirmed its outlook for fiscal 2025 and initiated guidance for 2026...
Nasdaq News: Markets·27d ago
News Placeholder
Billiontoone (NASDAQ:BLLN) Now Covered by Guggenheim
Guggenheim initiated coverage on Billiontoone in a report on Tuesday. They issued a "buy" rating and a $120.00 price target on the stock...
MarketBeat·1mo ago
News Placeholder
BillionToOne Announces Selection of Northstar Select as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
BillionToOne Announces Selection of Northstar Select as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East BillionToOne Announces Selection of...
PR Newswire·1mo ago
<
1
2
...
>

Latest BLLN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.